The findings of this study explored for the first time the role of aberrant HIF1α activation in DDD pathogenesis in vivo and further showed that inhibition of either aberrant HIF1α activation or HIF1α activation-mediated glycolysis can attenuate DDD pathology. This evidence concerns the gene HIF1A and Dowling-Degos disease 1.